Inactive Instrument

Highlights SWEDISH ORPHAN BIOVITRUM London S.E.

Equities

0GY1

End-of-day quote London S.E. Other stock markets
- ^SEK	-

06-19	Sobi Wins EU Approval for Hemophilia A Drug Altuvoct	MT
06-19	European Commission Grants Sobi® Marketing Authorisation for Altuvoct? for Treatment of Haemophilia A	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

European Commission Grants Sobi® Marketing Authorisation for Altuvoct? for Treatment of Haemophilia A	06-19	CI
BerGenBio ASA Enter into A Clinical Trial Agreement with the Mays Cancer Center At the University of Texas Health Science Center At San Antonio and Swedish Orphan Biovitrum AB	05-28	CI
Sobi Finalizes Inaugural SEK3 Billion Bond Issue	05-08	MT
Sobi Secures Additional EU Indication for Rare Blood Disorder Therapy	05-08	MT
Sobi Wins EU Regulatory Panel's Positive Opinion for Hemophilia A Drug	04-26	MT
Sobi Receives Positive CHMP Opinion Recommending Approval of efanesoctocog alfa for Once-Weekly Treatment of Haemophilia A	04-26	CI
Sobi's SEK10 Billion Note Program Gets Regulatory Nod in Sweden	04-26	MT
Swedish Orphan Biovitrum AB Reports Earnings Results for the First Quarter Ended March 31, 2024	04-25	CI
Swedish Orphan Biovitrum AB Provides Earnings Guidance for 2024	04-25	CI
Sobi to Expand in South Korea via Rare Disease JV with Handok	02-13	MT
Orexo, Swedish Orphan Biovitrum to Further Explore AmorphOX Combination	02-12	MT
Orexo AB (Publ.) and Swedish Orphan Biovitrum AB (publ.) Agrees to Advance Feasibility Study with Amorphox	02-12	CI
Sobi's Growth Potential Remains 'Tremendous' Amid Conservative FY24 Outlook, RBC Says	02-09	MT
Swedish Orphan Biovitrum AB Provides Revenue Guidance for the Year 2024	02-08	CI
Swedish Orphan Biovitrum AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-08	CI
Swedish Orphan Biovitrum AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-08	CI
Sobi's Profit to Get Royalty Boost as Sanofi Partnerships Outperform, RBC Says	02-02	MT
Swedish Orphan Biovitrum Completes Issuance, Repurchase of Convertible Shares	11-02	MT
Selecta Biosciences, Inc. and Swedish Orphan Biovitrum AB (Publ.) Enter into Amendment No. 1 to the License and Development Agreement	31/10/23	CI
Swedish Orphan Biovitrum AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	30/10/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights SWEDISH ORPHAN BIOVITRUM London S.E.

Equities

0GY1

Highlights

Filters